Openbookopenbook
Equity
Scinai Immunotherapeutics Ltd(SCNI)
USD --+0.00%
Reward60Moderate
Risk73High
📊75%Data
Strong 448% profit margin · Revenue growing 36% YoY
SCNI
+0.0 · +0.00%
USD · NASDAQ
Scinai Immunotherapeutics Ltd | Healthcare
Profitless Growth
Market Cap:2.83M
ℹ️
Reward Rating
60
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
73
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SCNI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $700.00.

What is Scinai Immunotherapeutics Ltd?

, a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel.

SCNI · Verdict

Solid reward · high risk

SCNI's standout is growth; volatility and profitability weigh on the picture.

Based on 88% data coverage

SCNI · Verdict

What’s working & what to watch

Strengths 1

  • Growth87/100

    Top decile vs peers

Watchouts 5

  • Volatility20/100

    Weak vs peers

  • Profitability34/100

    729% net margin · 18% ROE

  • Balance sheet35/100

    Current ratio 1.32

  • Cash flow37/100

    -965% free-cash-flow margin

  • Valuation41/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Scinai Immunotherapeutics Ltd?

, a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.83M, and a P/E ratio of 0.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap2.83M
P/E Ratio0.2222
Dividend YieldN/A
52 Week High3.92
52 Week Low0.613
Last AnnualDecember
IPO Date5/12/2015
IncorporatedUSA
Shares Outstanding3M
No. of Employees31
IndustryBiotechnology
ExchangeNASDAQ
Beta1.889
CurrencyUSD
Websitewww.scinai.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.